Gilead stock sprinted to a profit-taking zone Thursday after Gilead Sciences rode its Covid treatment to another beat and ...

Despite a mission to become a dominant cancer drug player, Gilead Sciences has as of late been locked in on its ...

Gilead Sciences ( GILD) increased its growth forecast for the year on strong third quarter results, marking a shift away from ...

Gilead Sciences (NASDAQ: GILD) recently broke its 52-week high and is up over 40% over the past six months. As a leading ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions.

Gilead Sciences' Q3 2024 results exceeded expectations, driven by a strong performance of the HIV portfolio. Read why I ...

Gilead Sciences (GILD) is scheduled to announce Q3 earnings results on Wednesday, November 6th, after market close. Leerink ...

Leerink Partners analyst Daina Graybosch has maintained their bullish stance on GILD stock, giving a Buy rating yesterday. Daina ...

Needham analyst Joseph Stringer has maintained their neutral stance on GILD stock, giving a Hold rating today. Joseph Stringer’s rating is based on a combination of factors including Gilead Sciences’ ...

US biotech major Gilead Sciences was trading nearly 2% higher in pre-market on Thursday after announcing its third-quarter ...

The Supreme Court of California is gearing up to decide an important question for the future of product liability law: Do drug manufacturers have ...